- Home
- SPB vs GHRS Comparison
SPB vs GHRS Comparison
Compare SPB & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPB | GHRS |
|---|---|---|
| Founded | 1906 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | 73 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPB | GHRS |
|---|---|---|
| Price | $86.98 | $28.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $82.40 | $41.38 |
| AVG Volume (30 Days) | ★ 369.4K | 322.3K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $3,802,100,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $1.85 | N/A |
| P/E Ratio | $85.31 | ★ N/A |
| Revenue Growth | ★ 20.86 | N/A |
| 52 Week Low | $49.99 | $11.83 |
| 52 Week High | $99.06 | $31.44 |
Technical Indicators
Market Signals| Indicator | SPB | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 48.98 |
| Support Level | $85.81 | $28.05 |
| Resistance Level | $90.60 | $28.96 |
| Average True Range (ATR) | 3.07 | 1.50 |
| MACD | -0.48 | -0.24 |
| Stochastic Oscillator | 11.16 | 11.46 |
Price Performance
Historical ComparisonAbout SPB Spectrum Brands Holdings Inc.
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, which generates maximum revenue; Global Pet Care; and Home and Garden. The company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific. It generates maximum revenue from North America.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.